Is Baudax Bio, Inc. overvalued or undervalued?

As of 12 May 2023, Baudax Bio, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued given its financial metrics and peer comparisons. Notably, Baudax has a P/E ratio of 0.00, an EV to EBIT of -0.65, and an EV to EBITDA of -0.66, all of which indicate significant financial distress.
In comparison to its peers, Baudax Bio, Inc. stands out negatively against companies such as ABVC BioPharma, Inc., which has a P/E ratio of -15.31, and Plus Therapeutics, Inc., with a P/E ratio of -0.43. The substantial negative return over the past year of -100% further emphasizes the company's struggles, especially when juxtaposed with the S&P 500's positive return of 10.26% during the same period. Overall, Baudax Bio, Inc. is deemed overvalued based on its current financial standing and performance relative to its peers.